| Fiore J Devito, MD | |
|
6 Brighton Rd, Clifton, NJ 07012-1647 | |
| (973) 743-6447 | |
| (973) 743-6918 |
| Full Name | Fiore J Devito |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 43 Years |
| Location | 6 Brighton Rd, Clifton, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679599609 | NPI | - | NPPES |
| 1529005 | Medicaid | NJ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | 25MA04454000 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hackensackumc Mountainside | Montclair, NJ | Hospital |
| Clara Maass Medical Center | Belleville, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Summit Medical Group Pa | 5395642276 | 1253 |
News Archive
AdvanSource Biomaterials Corporation, a leading developer, manufacturer and seller of advanced polymer technologies and materials for a broad range of medical devices, today announced that it has received a "Notice of Allowance" from the U.S. Patent and Trademark Office in connection with its antimicrobial patent application filed in June 2007. U.S. Patent No. 7,772,296, which is entitled "Antimicrobial Polyurethane Resins and Products Made Therefrom," covers a drug-free, antimicrobial technology to eradicate Methicillin-resistant Staphylococcus aureus ("MRSA") clinical infections associated with medical devices.
A novel minimally invasive surgery for young children living with a difficult-to-treat progressive form of scoliosis, known as juvenile idiopathic scoliosis, may eliminate the need for spinal fusion later in adolescence, according to new research by surgeons from Children's Mercy Hospitals and Clinics in Kansas City, Mo. The study was presented at the American Academy of Pediatrics National Conference and Exhibition in San Francisco.
The U.S. Food and Drug Administration today sent a warning letter to Procter & Gamble notifying the company that its Vicks DayQuil Plus Vitamin C and Vicks Nyquil Plus Vitamin C are illegally marketed combinations of drug ingredients and a dietary ingredient.
Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the companies have submitted their reply to a complete response letter issued last month by the U.S. Food and Drug Administration (FDA) after review of the New Drug Application (NDA) submission for BYDUREON™ (exenatide for extended-release injectable suspension).
The National Institutes of Health (NIH) has awarded researchers at Albert Einstein College of Medicine at Yeshiva University a five-year, $5.9 million grant to develop a new vaccine against tuberculosis (TB), including the toughest-to-treat forms of the disease known as multi drug-resistant and extensively drug-resistant. The grant will build on a new approach to TB vaccine design that is based on genetically altered Mycobacterium smegmatis, which is closely related to the bacterial species (Mycobacterium tuberculosis) that causes TB in humans.
› Verified 3 days ago
| Entity Name | Summit Medical Group Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942254347 PECOS PAC ID: 5395642276 Enrollment ID: O20031218000011 |
News Archive
AdvanSource Biomaterials Corporation, a leading developer, manufacturer and seller of advanced polymer technologies and materials for a broad range of medical devices, today announced that it has received a "Notice of Allowance" from the U.S. Patent and Trademark Office in connection with its antimicrobial patent application filed in June 2007. U.S. Patent No. 7,772,296, which is entitled "Antimicrobial Polyurethane Resins and Products Made Therefrom," covers a drug-free, antimicrobial technology to eradicate Methicillin-resistant Staphylococcus aureus ("MRSA") clinical infections associated with medical devices.
A novel minimally invasive surgery for young children living with a difficult-to-treat progressive form of scoliosis, known as juvenile idiopathic scoliosis, may eliminate the need for spinal fusion later in adolescence, according to new research by surgeons from Children's Mercy Hospitals and Clinics in Kansas City, Mo. The study was presented at the American Academy of Pediatrics National Conference and Exhibition in San Francisco.
The U.S. Food and Drug Administration today sent a warning letter to Procter & Gamble notifying the company that its Vicks DayQuil Plus Vitamin C and Vicks Nyquil Plus Vitamin C are illegally marketed combinations of drug ingredients and a dietary ingredient.
Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the companies have submitted their reply to a complete response letter issued last month by the U.S. Food and Drug Administration (FDA) after review of the New Drug Application (NDA) submission for BYDUREON™ (exenatide for extended-release injectable suspension).
The National Institutes of Health (NIH) has awarded researchers at Albert Einstein College of Medicine at Yeshiva University a five-year, $5.9 million grant to develop a new vaccine against tuberculosis (TB), including the toughest-to-treat forms of the disease known as multi drug-resistant and extensively drug-resistant. The grant will build on a new approach to TB vaccine design that is based on genetically altered Mycobacterium smegmatis, which is closely related to the bacterial species (Mycobacterium tuberculosis) that causes TB in humans.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Fiore J Devito, MD 1 Diamond Hill Rd, Berkeley Heights, NJ 07922-2104 Ph: (908) 273-4300 | Fiore J Devito, MD 6 Brighton Rd, Clifton, NJ 07012-1647 Ph: (973) 743-6447 |
News Archive
AdvanSource Biomaterials Corporation, a leading developer, manufacturer and seller of advanced polymer technologies and materials for a broad range of medical devices, today announced that it has received a "Notice of Allowance" from the U.S. Patent and Trademark Office in connection with its antimicrobial patent application filed in June 2007. U.S. Patent No. 7,772,296, which is entitled "Antimicrobial Polyurethane Resins and Products Made Therefrom," covers a drug-free, antimicrobial technology to eradicate Methicillin-resistant Staphylococcus aureus ("MRSA") clinical infections associated with medical devices.
A novel minimally invasive surgery for young children living with a difficult-to-treat progressive form of scoliosis, known as juvenile idiopathic scoliosis, may eliminate the need for spinal fusion later in adolescence, according to new research by surgeons from Children's Mercy Hospitals and Clinics in Kansas City, Mo. The study was presented at the American Academy of Pediatrics National Conference and Exhibition in San Francisco.
The U.S. Food and Drug Administration today sent a warning letter to Procter & Gamble notifying the company that its Vicks DayQuil Plus Vitamin C and Vicks Nyquil Plus Vitamin C are illegally marketed combinations of drug ingredients and a dietary ingredient.
Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the companies have submitted their reply to a complete response letter issued last month by the U.S. Food and Drug Administration (FDA) after review of the New Drug Application (NDA) submission for BYDUREON™ (exenatide for extended-release injectable suspension).
The National Institutes of Health (NIH) has awarded researchers at Albert Einstein College of Medicine at Yeshiva University a five-year, $5.9 million grant to develop a new vaccine against tuberculosis (TB), including the toughest-to-treat forms of the disease known as multi drug-resistant and extensively drug-resistant. The grant will build on a new approach to TB vaccine design that is based on genetically altered Mycobacterium smegmatis, which is closely related to the bacterial species (Mycobacterium tuberculosis) that causes TB in humans.
› Verified 3 days ago
Dr. Ahmed Abdel Mekkawy, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 925 Clifton Ave, Suite 101, Clifton, NJ 07013 Phone: 973-778-5070 Fax: 973-778-2878 | |
Dr. Pearl Korenblit, M.D. Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 1011 Clifton Ave, First Floor, Clifton, NJ 07013 Phone: 973-928-5490 Fax: 973-928-5493 | |
Louise Ashley Albornoz, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 1011 Clifton Ave, Clifton, NJ 07013 Phone: 973-778-6611 Fax: 973-473-8434 | |
Dr. Fadwa Sumrein, D.O Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 2 Brighton Rd Ste 400, Clifton, NJ 07012 Phone: 862-297-9696 Fax: 862-297-9695 | |
Joanna Crincoli, DO Gastroenterology Medicare: Medicare Enrolled Practice Location: 10 Frances St Fl 2, Clifton, NJ 07014 Phone: 973-902-4449 | |
Dr. Ravinder M Narang, M.D. Gastroenterology Medicare: Medicare Enrolled Practice Location: 721 Clifton Ave, Clifton, NJ 07013 Phone: 973-471-9454 | |
Kedar Sankholkar, MD, MS Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1030 Clifton Ave, Clifton, NJ 07013 Phone: 973-778-3777 Fax: 973-778-3252 |